Prometheus Biosciences Inc Stock News

Over the past 3 months, 6 analysts have published their opinion on Prometheus Biosciences (NASDAQ: RXDX ) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company''s business to predict how a stock will trade over the upcoming year. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 5 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 0 1 0 0 0 3M Ago 0 4 0 0 0 According to 6 analyst offering 12-month price targets in the last 3 months, Prometheus Biosciences has an average price target of $48.33 with a high of $62.00 and a low of $42.00. Below … Full story available on Benzinga.com

SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development

Check out these health care firms taking center stage in the stock market now.

Prometheus Biosciences Inc (RXDX) shares closed today 17.1% higher than it did at the end of yesterday. The stock is currently down 10.7% year-to-date, up 39.5% over the past 12 months, and up 39.5% over the past five years. Today, the Dow Jones Industrial Average fell 0.6%, and the S&P 500 rose 0.0%. Trading Activity Shares traded as high as $36.87 and as low as $29.50 this week.Shares closed 12.8% below its 52-week high and 119.1% above its 52-week low.Trading volume this week was 28.5% higher than the 10-day average and 76.3% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price beats the S&P 500 Index today, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, beats it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 103.4% The company's stock price performance over the past 12 months beats the peer average by -233.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Prometheus Biosciences Inc (RXDX) shares closed today 17.1% higher than it did at the end of yesterday. The stock is currently down 10.7% year-to-date, up 39.5% over the past 12 months, and up 39.5% over the past five years. Today, the Dow Jones Industrial Average fell 0.6%, and the S&P 500 rose 0.0%. Trading Activity Shares traded as high as $36.87 and as low as $29.50 this week.Shares closed 12.8% below its 52-week high and 119.1% above its 52-week low.Trading volume this week was 43.4% higher than the 10-day average and 1.3% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 8.6% higher than its 5-day moving average, 0.6% lower than its 20-day moving average, and 15.4% higher than its 90-day moving average. Market Comparative Performance The company's share price beats the S&P 500 Index today, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, beats it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 115.7% The company's stock price performance over the past 12 months beats the peer average by -229.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development

Prometheus Biosciences Inc (RXDX) shares closed today 10.7% higher than it did at the end of yesterday. The stock is currently up 17.9% year-to-date, up 17.9% over the past 12 months, and up 17.9% over the past five years. Today, the Dow Jones Industrial Average fell 1.2%, and the S&P 500 fell 1.1%. Trading Activity Shares traded as high as $35.47 and as low as $28.74 this week.Shares closed 17.5% below its 52-week high and 104.8% above its 52-week low.Trading volume this week was 234.4% higher than the 10-day average and 560.8% higher than the 30-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -198.9% The company's stock price performance over the past 12 months beats the peer average by -176.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Global IPOs have raised $453 billion in proceeds, representing a 67% increase year-over-year and a more than doubling from 2019 levels.

Wells Fargo & Company initiated coverage on shares of Prometheus Biosciences (NASDAQ:RXDX) in a report released on Wednesday morning, Price Targets.com reports. The brokerage issued an overweight rating and a $42.00 price objective on the biopharmaceutical companys stock. Other equities analysts also recently issued reports about the stock. SVB Leerink upped their target price on []

Wells Fargo & Company started coverage on shares of Prometheus Biosciences (NASDAQ:RXDX) in a research report sent to investors on Wednesday morning, Analyst Ratings Network reports. The firm issued an overweight rating and a $42.00 target price on the biopharmaceutical companys stock. Several other research analysts also recently commented on RXDX. SVB Leerink lifted their []

Check out these biotech stocks turning heads in the stock market now.

Prometheus: Biotech To Watch With A Monoclonal Antibody For Immune-Mediated Diseases

Phase 1 trial achieved primary objective of safety and tolerability and demonstrated favorable outcomes on other key endpoints, including target engagement and immunogenicity

Prometheus Biosciences, Inc. (NASDAQ:RXDX) was the recipient of a large decline in short interest in November. As of November 15th, there was short interest totalling 897,900 shares, a decline of 19.8% from the October 31st total of 1,120,000 shares. Based on an average daily trading volume, of 141,500 shares, the short-interest ratio is currently 6.3 [] The post Prometheus Biosciences, Inc. (NASDAQ:RXDX) Short Interest Down 19.8% in November appeared first on ETF Daily News .